## Andreas Kjær

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3691545/publications.pdf

Version: 2024-02-01

19657 31849 17,816 619 61 101 citations h-index g-index papers 637 637 637 20505 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Myocardial perfusion recovery induced by an î±-calcitonin gene-related peptide analogue. Journal of Nuclear Cardiology, 2022, 29, 2090-2099.	2.1	5
2	Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia. Journal of Nuclear Medicine, 2022, 63, 431-437.	5.0	9
3	A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup> Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2022, 63, 376-383.	5.0	6
4	Amiodarone attenuates cardiac Rubidium-82 in consecutive PET/CT scans in a rodent model. Journal of Nuclear Cardiology, 2022, 29, 2853-2862.	2.1	4
5	Matrix effect in tumor lysates – Does it affect your cytokine ELISA and multiplex analyses?. Journal of Immunological Methods, 2022, 500, 113177.	1.4	1
6	A new uPAR-targeting fluorescent probe for optical guided intracranial surgery in resection of a meningiomaâ€"a case report. Acta Neurochirurgica, 2022, 164, 267-271.	1.7	3
7	Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with <sup>18</sup> F-FDG PET/CT: A Single-Center Prospective Study. Journal of Nuclear Medicine, 2022, 63, 1169-1176.	5.0	9
8	Prospective Phase II Trial of Prognostication by <sup>68</sup> Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. Journal of Nuclear Medicine, 2022, 63, 1371-1377.	5.0	13
9	Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. Diabetes, 2022, 71, 812-820.	0.6	5
10	Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists. Journal of Controlled Release, 2022, 342, 337-344.	9.9	24
11	Image-derived and physiological markers to predict adequate adenosine-induced hyperemic response in Rubidium-82 myocardial perfusion imaging. Journal of Nuclear Cardiology, 2022, 29, 3207-3217.	2.1	2
12	Development of 18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging. Pharmaceuticals, 2022, 15, 245.	3.8	14
13	Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability. Molecular Imaging and Biology, 2022, 24, 600-611.	2.6	1
14	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Frontiers in Clinical Diabetes and Healthcare, 2022, 3, .	0.8	0
15	Deep learning for Dixon MRI-based attenuation correction in PET/MRI of head and neck cancer patients. EJNMMI Physics, 2022, 9, 20.	2.7	5
16	In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [64Cu]Cu-DOTA-AE105 positron emission tomography (PET). Atherosclerosis, 2022, 352, 103-111.	0.8	2
17	PET in vivo generators 134Ce and 140Nd on an internalizing monoclonal antibody probe. Scientific Reports, 2022, 12, 3863.	3.3	4
18	First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin $\hat{l}\pm\nu\hat{l}^2$ 3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability. Diagnostics, 2022, 12, 851.	2.6	2

#	Article	IF	CITATIONS
19	A White Plaque, Associated with Genomic Deletion, Derived from M13KE-Based Peptide Library Is Enriched in a Target-Unrelated Manner during Phage Display Biopanning Due to Propagation Advantage. International Journal of Molecular Sciences, 2022, 23, 3308.	4.1	4
20	Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis, 2022, 352, 88-95.	0.8	13
21	Multi-parametric PET/MRI for enhanced tumor characterization of patients with cervical cancer. European Journal of Hybrid Imaging, 2022, 6, 7.	1.5	3
22	Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2022, 23, 806-817.	3.0	13
23	Long-term outcomes after video-assisted thoracoscopic surgery in pulmonary large-cell neuroendocrine carcinoma. Surgical Oncology, 2022, 41, 101728.	1.6	5
24	Optimization of the left ventricle ejection fraction estimate obtained during cardiac adenosine stress 82Rubidium-PET scanning: impact of different reconstruction protocols. Journal of Nuclear Cardiology, 2022, 29, 3369-3378.	2.1	3
25	Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation. Scientific Reports, 2022, 12, 6185.	3.3	14
26	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the <scp>LIRAFLAME</scp> randomized, doubleâ€blinded, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1638-1642.	4.4	1
27	First-in-Humans PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using <sup>18</sup> F-labeled Active-Site Inhibited Factor VII ( <sup>18</sup> F-ASIS): Potential as Companion Diagnostic. Journal of Nuclear Medicine, 2022, 63, 1871-1879.	5.0	3
28	A convolutional neural network for total tumor segmentation in $[64Cu]Cu$ -DOTATATE PET/CT of patients with neuroendocrine neoplasms. EJNMMI Research, 2022, 12, .	2.5	10
29	Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model. Pharmaceutics, 2022, 14, 1284.	4.5	3
30	Expression patterns of uPAR, TF and EGFR and their potential as targets for molecular imaging in oropharyngeal squamous cell carcinoma. Oncology Reports, 2022, 48, .	2.6	2
31	No changes in myocardial perfusion following radiation therapy of left-sided breast cancer: A positron emission tomography study. Journal of Nuclear Cardiology, 2021, 28, 1923-1932.	2.1	9
32	Test–retest repeatability and software reproducibility of myocardial flow measurements using rest/adenosine stress Rubidium-82 PET/CT with and without motion correction in healthy young volunteers. Journal of Nuclear Cardiology, 2021, 28, 2860-2871.	2.1	16
33	[68Ga]Ga-NODAGA-E[(cRGDyK)]2 PET and hyperpolarized [1-13C] pyruvate MRSI (hyperPET) in canine cancer patients: simultaneous imaging of angiogenesis and the Warburg effect. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 395-405.	6.4	8
34	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 354-359.	5.0	16
35	<sup>18</sup> F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. Journal of Nuclear Medicine, 2021, 62, 808-815.	5.0	53
36	<sup>18</sup> F-FLT PET/CT Adds Value to <sup>18</sup> F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 628-635.	5.0	8

#	Article	IF	Citations
37	Fluorineâ€18 labeled aldehydes as prosthetic groups for oxime coupling with a FVIIa protein. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 198-208.	1.0	1
38	Nonâ€invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. Diabetic Medicine, 2021, 38, e14517.	2.3	4
39	Direct Cu-mediated aromatic <sup>18</sup> F-labeling of highly reactive tetrazines for pretargeted bioorthogonal PET imaging. Chemical Science, 2021, 12, 11668-11675.	7.4	36
40	Evaluation of [64Cu]Cu-NOTA-PEG7-H-Tz for Pretargeted Imaging in LS174T Xenograftsâ€"Comparison to [111In]In-DOTA-PEG11-BisPy-Tz. Molecules, 2021, 26, 544.	3.8	16
41	Flow Cytometric Evaluation of the Ongoing Angiogenic Response in Rat Cardiac Tissue Following Myocardial Infarction. Current Protocols, 2021, 1, e40.	2.9	1
42	Lipophilicity and Click Reactivity Determine the Performance of Bioorthogonal Tetrazine Tools in Pretargeted <i>In Vivo</i> Chemistry. ACS Pharmacology and Translational Science, 2021, 4, 824-833.	4.9	45
43	Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics, 2021, 11, 279.	2.6	3
44	Semiautomatic Tumor Delineation for Evaluation of <sup>64</sup> Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume. Journal of Nuclear Medicine, 2021, 62, 1564-1570.	5.0	20
45	Initial Experience with 64Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET. Diagnostics, 2021, 11, 350.	2.6	3
46	Surgery of the primary tumour in 201 patients with highâ€grade gastroenteropancreatic neuroendocrine and mixed neuroendocrineâ€nonâ€neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e12967.	2.6	23
47	Effective Intratumoral Retention of [ <sup>103</sup> Pd]AuPd Alloy Nanoparticles Embedded in Gelâ€Forming Liquids Paves the Way for New Nanobrachytherapy. Advanced Healthcare Materials, 2021, 10, e2002009.	7.6	8
48	Carotid plaque inflammatory activity assessed by 2-[18F]FDG-PET imaging decrease after a neurological thromboembolic event. EJNMMI Research, 2021, 11, 30.	2.5	0
49	A short report of 50 patients with gastroenteropancreatic mixed neuroendocrine–non-neuroendocrine neoplasms (MiNEN). Acta Oncológica, 2021, 60, 808-812.	1.8	7
50	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol $\tilde{A}^3$ gica, 2021, 60, 931-941.	1.8	32
51	Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence. European Journal of Surgical Oncology, 2021, 47, 1357-1363.	1.0	16
52	uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics, 2021, 11, 1087.	2.6	6
53	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. European Journal of Radiology, 2021, 139, 109668.	2.6	4
54	Lipolysis drives expression of the constitutively active receptor GPR3 to induce adipose thermogenesis. Cell, 2021, 184, 3502-3518.e33.	28.9	68

#	Article	IF	Citations
55	Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer, 2021, 156, 109-116.	2.0	13
56	Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients. Acta $Oncol\tilde{A}^3$ gica, 2021, 60, 1045-1053.	1.8	15
57	The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma. Oncotarget, 2021, 12, 1366-1376.	1.8	5
58	Optical tissue clearing and machine learning can precisely characterize extravasation and blood vessel architecture in brain tumors. Communications Biology, 2021, 4, 815.	4.4	9
59	Effect of Liraglutide on Arterial Inflammation Assessed as [ <sup>18</sup> F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Cardiovascular Imaging, 2021, 14, e012174.	2.6	18
60	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	2.6	5
61	Increase of Kiâ€67 index and influence on mortality in patients with neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e13018.	2.6	6
62	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <scp>LIRAFLAME</scp> randomized <scp>placeboâ€controlled</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	4.4	7
63	A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. EJNMMI Research, 2021, 11, 84.	2.5	1
64	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Research and Care, 2021, 9, e002395.	2.8	14
65	[68Ga]Ga-NODAGA-E[(cRGDyK)]2 Angiogenesis PET/MR in a Porcine Model of Chronic Myocardial Infarction. Diagnostics, 2021, 11, 1807.	2.6	4
66	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 2021, 11, 18522.	3.3	21
67	IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts. Theranostics, 2021, 11, 7159-7174.	10.0	11
68	Carbohydrate based biomarkers enable hybrid near infrared fluorescence and <sup>64</sup> Cu based radio-guidance for improved surgical precision. Nanotheranostics, 2021, 5, 448-460.	5.2	3
69	Effect of apoA-l PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins. ACS Omega, 2021, 6, 871-880.	3.5	2
70	<sup>64</sup> Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection. Journal of Nuclear Medicine, 2021, 62, 73-80.	5 <b>.</b> 0	29
71	Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy. Journal of Nanotheranostics, 2021, 2, 196-207.	3.1	4
72	Uptake of [68Ga]-NODAGA-E[(cRGDyK)]2 is related to improvement in pump function in rats with chronic ischemic cardiomyopathy treated with cell therapy. European Heart Journal, 2021, 42, .	2.2	0

#	Article	IF	CITATIONS
73	Altered brown fat thermoregulation and enhanced cold-induced thermogenesis in young, healthy, winter-swimming men. Cell Reports Medicine, 2021, 2, 100408.	6.5	17
74	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. International Journal of Cardiovascular Imaging, 2021, , 1.	<b>1.</b> 5	6
75	Development of the First Aliphatic <sup>18</sup> F-Labeled Tetrazine Suitable for Pretargeted PET Imagingâ€"Expanding the Bioorthogonal Tool Box. Journal of Medicinal Chemistry, 2021, 64, 15297-15312.	6.4	25
76	The Initial Cardiac Tissue Response to Cryopreserved Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells in Rats with Chronic Ischemic Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 11758.	4.1	5
77	Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors. Diagnostics, 2021, 11, 2030.	2.6	12
78	Photothermal Therapy as Adjuvant to Surgery in an Orthotopic Mouse Model of Human Fibrosarcoma. Cancers, 2021, 13, 5820.	3.7	8
79	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. Frontiers in Endocrinology, 2021, 12, 790405.	3.5	16
80	Optimization and Evaluation of Al18F Labeling Using a NOTAâ€"or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. Frontiers in Nuclear Medicine, 2021, 1, .	1.2	2
81	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. Frontiers in Endocrinology, 2021, 12, 780679.	3.5	4
82	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. Journal of Nuclear Cardiology, 2020, 27, 1698-1707.	2.1	15
83	123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. Journal of Nuclear Cardiology, 2020, 27, 931-939.	2.1	5
84	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of <sup>89</sup> Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjugate Chemistry, 2020, 31, 360-368.	3.6	22
85	Reproducibility of LVEF, LV volumes, and LV mass between Rubidium-82 PET/CT scans in young healthy volunteers using two commercially available software packages. Journal of Nuclear Cardiology, 2020, 27, 1237-1245.	2.1	9
86	FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy. European Archives of Oto-Rhino-Laryngology, 2020, 277, 539-547.	1.6	16
87	Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1302-1313.	6.4	55
88	<i>Trans</i> -Cyclooctene-Functionalized PeptoBrushes with Improved Reaction Kinetics of the Tetrazine Ligation for Pretargeted Nuclear Imaging. ACS Nano, 2020, 14, 568-584.	14.6	50
89	Quantitative determination of 64Cu-liposome accumulation at inflammatory and infectious sites: Potential for future theranostic system. Journal of Controlled Release, 2020, 327, 737-746.	9.9	14
90	64Cu-DOTATATE Positron Emission Tomography (PET) of Borrelia Burgdorferi Infection: In Vivo Imaging of Macrophages in Experimental Model of Lyme Arthritis. Diagnostics, 2020, 10, 790.	2.6	3

#	Article	IF	CITATIONS
91	Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDG–PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis. Diagnostics, 2020, 10, 1030.	2.6	2
92	Feasibility of Multiparametric Positron Emission Tomography/Magnetic Resonance Imaging as a One-Stop Shop for Radiation Therapy Planning for Patients with Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1329-1338.	0.8	14
93	Conventional Treatment of Glioblastoma Reveals Persistent CD44+ Subpopulations. Molecular Neurobiology, 2020, 57, 3943-3955.	4.0	12
94	<p>Noninvasive Molecular Imaging of the Enhanced Permeability and Retention Effect by <sup>64</sup>Cu-Liposomes: In vivo Correlations with <sup>68</sup>Ga-RGD, Fluid Pressure, Diffusivity and <sup>18</sup>F-FDG</p> . International Journal of Nanomedicine, 2020, Volume 15, 8571-8581.	6.7	15
95	Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation. Diagnostics, 2020, 10, 802.	2.6	5
96	Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy. Science Advances, 2020, 6, .	10.3	49
97	Multimodal soft tissue markers for bridging high-resolution diagnostic imaging with therapeutic intervention. Science Advances, 2020, 6, eabb5353.	10.3	8
98	Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis. Scientific Reports, 2020, 10, 19138.	3.3	12
99	The GLP-1 receptor agonist Semaglutide decreases vascular inflammation in a rabbit model of advanced atherosclerosis. European Heart Journal, 2020, 41, .	2.2	0
100	Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics, 2020, 10, 881.	2.6	7
101	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. British Journal of Cancer, 2020, 123, 46-53.	6.4	13
102	18F-FDG positron emission tomography and diffusion-weighted magnetic resonance imaging for response evaluation of nanoparticle-mediated photothermal therapy. Scientific Reports, 2020, 10, 7595.	3.3	9
103	Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer. Clinical Biochemistry, 2020, 84, 31-37.	1.9	5
104	Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy. Nanotheranostics, 2020, 4, 142-155.	5.2	5
105	No effects of a 6â€week intervention with a glucagonâ€like peptideâ€1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1837-1846.	4.4	4
106	Pharmacokinetic analysis of [68Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2577-2588.	6.4	10
107	<sup>64</sup> Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. Journal of Nuclear Medicine, 2020, 61, 1491-1497.	5.0	27
108	Plasmonic Material Engineering for Targeted Therapeutics. Advanced Optical Materials, 2020, 8, 2000616.	7.3	2

#	Article	lF	CITATIONS
109	Diffusion weighted magnetic resonance imaging (DW-MRI) as a non-invasive, tissue cellularity marker to monitor cancer treatment response. BMC Cancer, 2020, 20, 134.	2.6	27
110	Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging. Molecular Imaging and Biology, 2020, 22, 1021-1030.	2.6	16
111	In vivo imaging of cell proliferation in meningioma using 3′-deoxy-3′-[18F]fluorothymidine PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1496-1509.	6.4	9
112	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 16.	6.8	16
113		5.0	48
114	P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. BMC Cancer, 2020, 20, 27.	2.6	34
115	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations. PLoS ONE, 2020, 15, e0231884.	2.5	11
116	Chronic Kidney Disease–Induced Vascular Calcification Impairs Bone Metabolism. Journal of Bone and Mineral Research, 2020, 36, 510-522.	2.8	24
117	Blocking of efflux transporters in rats improves translational validation of brain radioligands. EJNMMI Research, 2020, 10, 124.	2.5	12
118	Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging. Molecules, 2020, 25, 463.	3.8	21
119	18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study. European Journal of Hybrid Imaging, 2020, 4, 2.	1.5	2
120	Title is missing!. , 2020, 15, e0231884.		0
121	Title is missing!. , 2020, 15, e0231884.		O
122	Title is missing!. , 2020, 15, e0231884.		0
123	Title is missing!. , 2020, 15, e0231884.		O
124	Stomach interference in 82Rb-PET myocardial perfusion imaging. Journal of Nuclear Cardiology, 2019, 26, 1934-1942.	2.1	6
125	Myocardial perfusion during atrial fibrillation in patients with non-ischaemic systolic heart failure: a cross-sectional study using Rubidium-82 positron emission tomography/computed tomography. European Heart Journal Cardiovascular Imaging, 2019, 20, 233-240.	1.2	6
126	Radiolabeling and in vivo evaluation of [11C]AGH-44: a potential lead structure to develop a positron emission tomography radioligand for the 5-HT7 receptor. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 847-851.	1.5	1

#	Article	IF	Citations
127	Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Science Translational Medicine, $2019,11,.$	12.4	51
128	Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging. EJNMMI Research, 2019, 9, 49.	2.5	24
129	Diagnostics Receives First Impact Factor. Diagnostics, 2019, 9, 64.	2.6	1
130	Fractionated photothermal therapy in a murine tumor model: comparison with single dose $< lp >$ . International Journal of Nanomedicine, 2019, Volume 14, 5369-5379.	6.7	18
131	Near-infrared fluorescence imaging improves the nodal yield in neck dissection in oral cavity cancer – A randomized study. European Journal of Surgical Oncology, 2019, 45, 2151-2158.	1.0	8
132	The Authors' Reply:. JACC: Cardiovascular Imaging, 2019, 12, 946-947.	5.3	1
133	Site-specifically labeled <sup>89</sup> Zr-DFO-trastuzumab improves immuno-reactivity and tumor uptake for immuno-PET in a subcutaneous HER2-positive xenograft mouse model. Theranostics, 2019, 9, 4409-4420.	10.0	41
134	Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine. Cell Metabolism, 2019, 30, 963-975.e7.	16.2	109
135	Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6129-6138.	3.6	28
136	Dose-Dependent Effect of Caffeine onÂAdenosine-Induced Myocardial StressÂPerfusion in Rubidium-82 Positron-Emission Tomography/Computed Tomography. JACC: Cardiovascular Imaging, 2019, 12, 1102-1103.	5.3	12
137	Oxime Coupling of Active Site Inhibited Factor Seven with a Nonvolatile, Water-Soluble Fluorine-18 Labeled Aldehyde. Bioconjugate Chemistry, 2019, 30, 775-784.	3.6	1
138	[68Ga]Ga-DOTA-TOC PET/CT in the localization of head and neck paraganglioma compared with [18F]FDOPA PET/CT and [123I]MIBG SPECT/CT. Nuclear Medicine and Biology, 2019, 71, 47-53.	0.6	12
139	Caffeine and myocardial perfusion: a clinical perspective. European Heart Journal Cardiovascular Imaging, 2019, 20, 763-764.	1.2	1
140	Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence. Lung Cancer, 2019, 132, 141-149.	2.0	21
141	Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia, 2019, 39, 1407-1420.	3.9	22
142	Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals. Journal of Infectious Diseases, 2019, 221, 506-509.	4.0	14
143	Preparing data for multiparametric PET/MR imaging: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of [18F]FDG-PET and diffusion-weighted MRI in head and neck cancer. Physica Medica, 2019, 61, 1-7.	0.7	8
144	18F-FDG PET/MR-imaging in a $G\tilde{A}^{\P}$ ttingen Minipig model of atherosclerosis: Correlations with histology and quantitative gene expression. Atherosclerosis, 2019, 285, 55-63.	0.8	12

#	Article	IF	CITATIONS
145	Impaired myocardial perfusion is associated with increasing end-systolic- and end-diastolic volumes in patients with non-ischemic systolic heart failure: a cross-sectional study using Rubidium-82 PET/CT. BMC Cardiovascular Disorders, 2019, 19, 68.	1.7	2
146	Myocardial first pass perfusion assessed by cardiac magnetic resonance and coronary microvascular dysfunction in women with angina and no obstructive coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 238-246.	1.2	14
147	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. Diabetes, 2019, 68, 1277-1286.	0.6	13
148	A tumorsphere model of glioblastoma multiforme with intratumoral heterogeneity for quantitative analysis of cellular migration and drug response. Experimental Cell Research, 2019, 379, 73-82.	2.6	15
149	Very Early Response Evaluation by PET/MR in Patients with Lung Cancerâ€"Timing and Feasibility. Diagnostics, 2019, 9, 35.	2.6	5
150	Fluorine-18 Radiolabeling Strategiesâ€"Advantages and Disadvantages of Currently Applied Labeling Methods., 2019,, 29-103.		9
151	Affinity-Guided Conjugation to Antibodies for Use in Positron Emission Tomography. Bioconjugate Chemistry, 2019, 30, 881-887.	3.6	6
152	Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 986-990.	2.2	16
153	P3356Antiarrhythmic therapy with amiodarone decreases the uptake of 82-Rubidium-PET: studies in a rodent model. European Heart Journal, 2019, 40, .	2.2	0
154	P3357Reproducibility of myocardial flow reserve estimation using Rubidium-82 PET/CT scans in healthy, young volunteers: comparison of three commercially available software packages. European Heart Journal, 2019, 40, .	2.2	0
155	One-Step Synthesis of N-Succinimidyl-4-[18F]Fluorobenzoate ([18F]SFB). Molecules, 2019, 24, 3436.	3.8	10
156	CD4 <sup>+</sup> and CD8a <sup>+</sup> PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. Theranostics, 2019, 9, 8221-8238.	10.0	59
157	Coronary artery calcium and intimaâ€media thickness are associated with level of cytomegalovirus immunoglobulin G in HIVâ€infected patients. HIV Medicine, 2019, 20, 60-62.	2.2	10
158	Convenient Entry to <sup>18</sup> F‣abeled Amines through the Staudinger Reduction. European Journal of Organic Chemistry, 2019, 2019, 1722-1725.	2.4	6
159	Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology. Neoplasia, 2019, 21, 1-16.	<b>5.</b> 3	316
160	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. European Heart Journal Cardiovascular Imaging, 2019, 20, 796-803.	1,2	13
161	Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 603-613.	6.4	44
162	Early risk stratification using Rubidium-82 positron emission tomography in STEMI patients. Journal of Nuclear Cardiology, 2019, 26, 471-482.	2.1	4

#	Article	IF	CITATIONS
163	Rubidium-82 PET imaging is feasible in a rat myocardial infarction model. Journal of Nuclear Cardiology, 2019, 26, 798-809.	2.1	12
164	Improved surgical resection of metastatic pancreatic cancer using uPAR targeted <i>in vivo</i> fluorescent guidance: comparison with traditional white light surgery. Oncotarget, 2019, 10, 6308-6316.	1.8	14
165	PET/DW-MRI for evaluating treatment in chronic hepatitis C patients. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 84-92.	1.0	1
166	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	1.9	3
167	Platinum nanoparticles: a non-toxic, effective and thermally stable alternative plasmonic material for cancer therapy and bioengineering. Nanoscale, 2018, 10, 9097-9107.	5.6	94
168	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nature Biomedical Engineering, 2018, 2, 279-292.	22.5	94
169	Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 450-457.	2.1	26
170	Myocardial perfusion in patients with non-ischaemic systolic heart failure and type 2 diabetes: a cross-sectional study using Rubidium-82 PET/CT. International Journal of Cardiovascular Imaging, 2018, 34, 993-1001.	1.5	1
171	The Apolipoprotein M/S1P Axis Controls Triglyceride Metabolism and Brown Fat Activity. Cell Reports, 2018, 22, 175-188.	6.4	54
172	A blood biomarker for monitoring response to anti-EGFR therapy. Cancer Biomarkers, 2018, 22, 333-344.	1.7	3
173	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). European Radiology, 2018, 28, 4086-4101.	4.5	80
174	Acquired Resistance to a MET Antibody <i>In Vivo</i> Can Be Overcome by the MET Antibody Mixture Sym015. Molecular Cancer Therapeutics, 2018, 17, 1259-1270.	4.1	8
175	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 559-567.	1.1	16
176	Subacute cardiac rubidium-82 positron emission tomography (82Rb-PET) to assess myocardial area at risk, final infarct size, and myocardial salvage after STEMI. Journal of Nuclear Cardiology, 2018, 25, 970-981.	2.1	6
177	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. European Urology Focus, 2018, 4, 360-368.	3.1	7
178	<sup>123</sup> lâ€ <scp>MIBG</scp> imaging for detection of anthracyclineâ€induced cardiomyopathy. Clinical Physiology and Functional Imaging, 2018, 38, 176-185.	1.2	12
179	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. Clinical Genitourinary Cancer, 2018, 16, e181-e192.	1.9	4
180	Injectable iodine-125 labeled tissue marker for radioactive localization of non-palpable breast lesions. Acta Biomaterialia, 2018, 65, 197-202.	8.3	9

#	Article	IF	Citations
181	Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Annals of Nuclear Medicine, 2018, 32, 16-21.	2.2	8
182	Liposome accumulation in irradiated tumors display important tumor and dose dependent differences. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 27-34.	3.3	11
183	Liposomeâ€encapsulated chemotherapy: Current evidence for its use in companion animals. Veterinary and Comparative Oncology, 2018, 16, E1-E15.	1.8	13
184	Effects of menopause and high-intensity training on insulin sensitivity and muscle metabolism. Menopause, 2018, 25, 165-175.	2.0	21
185	223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity. Journal of Nuclear Medicine, 2018, 59, 596-602.	5.0	39
186	Site-Specific <sup>64</sup> Cu Labeling of the Serine Protease, Active Site Inhibited Factor Seven Azide (FVIIai-N <sub>3</sub> ), Using Copper Free Click Chemistry. Bioconjugate Chemistry, 2018, 29, 117-125.	3.6	4
187	Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer. Journal of Nuclear Medicine, 2018, 59, 999-1004.	5.0	15
188	Remote-loading of liposomes with manganese-52 and in vivo evaluation of the stabilities of 52Mn-DOTA and 64Cu-DOTA using radiolabelled liposomes and PET imaging. Journal of Controlled Release, 2018, 269, 100-109.	9.9	43
189	P4703Impaired myocardial perfusion is associated with increasing left ventricular mass in patients with non-ischaemic systolic heart failure: a cross-sectional study using Rubidium-82 PET/CT. European Heart Journal, 2018, 39, .	2.2	0
190	Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts. International Journal of Nanomedicine, 2018, Volume 13, 7647-7656.	6.7	15
191	Remote loading of liposomes with a <sup>124</sup> I-radioiodinated compound and their <i>in vivo</i> evaluation by PET/CT in a murine tumor model. Theranostics, 2018, 8, 5828-5841.	10.0	24
192	Pancreatic Islet Cell Tumors. , 2018, , 626-634.		0
193	Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized <sup>13</sup> C-MRSI. Theranostics, 2018, 8, 4765-4780.	10.0	35
194	Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery. Bioconjugate Chemistry, 2018, 29, 3833-3840.	3.6	62
195	Development of a Symmetric Echo-Planar Spectroscopy Imaging Framework for Hyperpolarized 13C Imaging in a Clinical PET/MR Scanner. Tomography, 2018, 4, 110-122.	1.8	5
196	Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics. ACS Nano, 2018, 12, 11386-11398.	14.6	45
197	Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G. Open Forum Infectious Diseases, 2018, 5, ofy205.	0.9	10
198	Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. Liver International, 2018, 38, 1614-1623.	3.9	30

#	Article	IF	CITATIONS
199	Functional brown adipose tissue and sympathetic activity after cold exposure in humans with type 1 narcolepsy. Sleep, 2018, 41, .	1.1	17
200	Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis. Cell Metabolism, 2018, 28, 159-174.e11.	16.2	114
201	VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro-Oncology, 2018, 20, 1462-1474.	1.2	56
202	Retention and Functional Effect of Adipose-Derived Stromal Cells Administered in Alginate Hydrogel in a Rat Model of Acute Myocardial Infarction. Stem Cells International, 2018, 2018, 1-13.	2.5	12
203	Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines. Biomaterials, 2018, 179, 209-245.	11.4	124
204	Non-invasive Early Response Monitoring of Nanoparticle-assisted Photothermal Cancer Therapy Using <sup>18</sup> F-FDG, <sup>18</sup> F-FLT, and <sup>18</sup> F-FET PET/CT Imaging. Nanotheranostics, 2018, 2, 201-210.	5.2	12
205	Effect of inhibition of CBP-coactivated $\hat{l}^2$ -catenin-mediated Wnt signalling in uremic rats with vascular calcifications. PLoS ONE, 2018, 13, e0201936.	2.5	11
206	Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes, 2018, 9, 337.	2.4	9
207	Association between smoking status assessed with plasmaâ€cotinine and inflammatory and endothelial biomarkers in <scp>HIV</scp> â€positive and <scp>HIV</scp> â€negative individuals. HIV Medicine, 2018, 19, 679-687.	2.2	10
208	An Uncommon Case of Pediatric Esthesioneuroblastoma Presenting as SIADH: 18F-FDG PET/CT in Staging and Post-Therapeutic Assessment. Diagnostics, 2018, 8, 8.	2.6	9
209	Angiogenesis PET Tracer Uptake (68Ga-NODAGA-E[(cRGDyK)]2) in Induced Myocardial Infarction and Stromal Cell Treatment in Minipigs. Diagnostics, 2018, 8, 33.	2.6	8
210	Combined hyperpolarized 13C-pyruvate MRS and 18F-FDG PET (hyperPET) estimates of glycolysis in canine cancer patients. European Journal of Radiology, 2018, 103, 6-12.	2.6	21
211	Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification. PLoS ONE, 2018, 13, e0190820.	2.5	17
212	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 127-136.	1.0	2
213	Semiâ€quantitative myocardial perfusion measured by computed tomography in patients with refractory angina: a headâ€toâ€head comparison with quantitative rubidiumâ€82 positron emission tomography as reference. Clinical Physiology and Functional Imaging, 2017, 37, 481-488.	1.2	4
214	Nonâ€ <scp>ECG</scp> â€gated <scp>CT</scp> pulmonary angiography and the prediction of right ventricular dysfunction in patients suspected of pulmonary embolism. Clinical Physiology and Functional Imaging, 2017, 37, 575-581.	1.2	15
215	Whole-Body <sup>18</sup> F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients. Journal of Nuclear Medicine, 2017, 58, 1058-1064.	5.0	27
216	Clinical utility of 18F-FDG positron emission tomography/computed tomography scan vs. 99mTc-HMPAO white blood cell single-photon emission computed tomography in extra-cardiac work-up of infective endocarditis. International Journal of Cardiovascular Imaging, 2017, 33, 751-760.	1.5	21

#	Article	IF	CITATIONS
217	Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. PET Clinics, 2017, 12, 243-255.	3.0	7
218	Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. International Journal of Cancer, 2017, 141, 191-199.	5.1	31
219	PET imaging with copperâ€64 as a tool for realâ€time <i>in vivo</i> investigations of the necessity for crossâ€linking of polymeric micelles in nanomedicine. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 366-374.	1.0	8
220	Hyperpolarized 13C-MRSI and PET (hyperPET) in an Osteomyelitis Pig Model: A Pilot Study. IEEE Transactions on Radiation and Plasma Medical Sciences, 2017, 1, 164-167.	3.7	1
221	Agreement between Estimated and Measured Renal Function in an Everyday Clinical Outpatient Setting of Human Immunodeficiency Virus-Infected Individuals. Nephron, 2017, 136, 318-327.	1.8	3
222	Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction. Peptides, 2017, 93, 1-12.	2.4	16
223	Transthoracic Doppler echocardiography compared with positron emission tomography for assessment of coronary microvascular dysfunction: The iPOWER study. International Journal of Cardiology, 2017, 228, 435-443.	1.7	43
224	Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1588-1601.	6.4	319
225	Urokinase Plasminogen Activator Receptor–PET with 68 Ga-NOTA-AE105. PET Clinics, 2017, 12, 311-319.	3.0	9
226	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA Psychiatry, 2017, 74, 719.	11.0	135
227	Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014. Acta Oncol $ ilde{A}^3$ gica, 2017, 56, 1204-1209.	1.8	31
228	The Authors Reply:. JACC: Cardiovascular Imaging, 2017, 10, 96-97.	<b>5.</b> 3	2
229	The Authors Reply:. JACC: Cardiovascular Imaging, 2017, 10, 94-95.	5.3	0
230	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology, 2017, 105, 212-244.	2.5	325
231	Improved positron emission tomography imaging of glioblastoma cancer using novel 68Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). Amino Acids, 2017, 49, 1089-1100.	2.7	7
232	Simultaneous imaging of hyperpolarized [1,4â€ <sup>13</sup> C <sub>2</sub> ]fumarate, [1â€ <sup>13</sup> C]pyruvate and <sup>18</sup> Fâ€"FDG in a rat model of necrosis in a clinical PET/MR scanner. NMR in Biomedicine, 2017, 30, e3803.	2.8	13
233	Uremia does not affect neointima formation in mice. Scientific Reports, 2017, 7, 6496.	3.3	4
234	Preliminary results for a multimodality imaging approach for early detection and prediction of cardiotoxicity in doxorubicinâ€treated patients with malignant lymphoma. Hematological Oncology, 2017, 35, 356-357.	1.7	1

#	Article	IF	CITATIONS
235	Perfusion imaging using rubidium-82 (82Rb) PET in rats with myocardial infarction: First small animal cardiac 82Rb-PET. Journal of Nuclear Cardiology, 2017, 24, 750-752.	2.1	7
236	Revisiting the use of sPLA 2 -sensitive liposomes in cancer therapy. Journal of Controlled Release, 2017, 261, 163-173.	9.9	38
237	Respiratory gating in cardiac PET: Effects of adenosine and dipyridamole. Journal of Nuclear Cardiology, 2017, 24, 1941-1949.	2.1	7
238	The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 421-431.	6.4	15
239	Comparison of rest and adenosine stress quantitative and semi-quantitative myocardial perfusion using magnetic resonance in patients with ischemic heart disease. Clinical Imaging, 2017, 41, 149-156.	1.5	3
240	Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2017, 58, 69-74.	5.0	44
241	Head-to-Head Comparison of <sup>64</sup> Cu-DOTATATE and <sup>68</sup> Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 451-457.	5.0	163
242	Assessment of muscle function using hybrid PET/MRI: comparison of 18F-FDG PET and T2-weighted MRI for quantifying muscle activation in human subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 704-711.	6.4	15
243	Safety, Dosimetry, and Tumor Detection Ability of <sup>68</sup> Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging. Journal of Nuclear Medicine, 2017, 58, 379-386.	5.0	58
244	Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by 82Rb PET/CT in HIV-Infected Patients. Diagnostics, 2017, 7, 31.	2.6	6
245	Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector. Frontiers in Medicine, 2017, 4, 98.	2.6	9
246	RESOLUTE PET/MRI Attenuation Correction for O-(2-18F-fluoroethyl)-L-tyrosine (FET) in Brain Tumor Patients with Metal Implants. Frontiers in Neuroscience, 2017, 11, 453.	2.8	27
247	18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy. PLoS ONE, 2017, 12, e0177997.	2.5	22
248	Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer, 2017, 17, 572.	2.6	32
249	FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Research, 2017, 7, 56.	2.5	6
250	uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model. Oncotarget, 2017, 8, 15407-15419.	1.8	51
251	Secretory phospholipase A 2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo. Journal of Controlled Release, 2017, 262, 212-221.	9.9	31
252	Using Optically Manipulated Metallic Nanoparticles for Cancer Treatment., 2017,,.		0

#	Article	IF	Citations
253	The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 255-262.	1.0	15
254	In Vivo Radionuclide Generators for Diagnostics and Therapy. Bioinorganic Chemistry and Applications, 2016, 2016, 1-8.	4.1	31
255	Diagnostics Now in PubMed and PubMed Central. Diagnostics, 2016, 6, 12.	2.6	1
256	Angiogenesis PET Tracer Uptake (68Ga-NODAGA-E[(cRGDyK)]2) in Induced Myocardial Infarction in Minipigs. Diagnostics, 2016, 6, 26.	2.6	6
257	18F-FET-PET in Primary Hyperparathyroidism: A Pilot Study. Diagnostics, 2016, 6, 30.	2.6	10
258	Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105. PLoS ONE, 2016, 11, e0147428.	2.5	35
259	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. Diabetes, 2016, 65, 3129-3138.	0.6	22
260	Microbiota-Dependent Marker TMAO is Not Associated With Decreased Myocardial Perfusion in Well-Treated HIV-Infected Patients as Assessed by 82Rubidium PET/CT. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e83-e85.	2.1	10
261	123I-MIBG Scintigraphy inÂtheÂSubacute State of Takotsubo Cardiomyopathy. JACC: Cardiovascular Imaging, 2016, 9, 982-990.	5.3	56
262	PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives. Clinical and Translational Imaging, 2016, 4, 457-465.	2.1	9
263	Myocardial perfusion of infarcted and normal myocardium in propofol-anesthetized minipigs using 82Rubidium PET. Journal of Nuclear Cardiology, 2016, 23, 599-603.	2.1	5
264	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. BMC Infectious Diseases, 2016, 16, 713.	2.9	61
265	PET Imaging of Tissue Factor in Pancreatic Cancer Using <sup>64</sup> Cu-Labeled Active Site–Inhibited Factor VII. Journal of Nuclear Medicine, 2016, 57, 1112-1119.	5.0	18
266	Simultaneous PET/MRI with 13C magnetic resonance spectroscopic imaging (hyperPET): phantom-based evaluation of PET quantification. EJNMMI Physics, 2016, 3, 7.	2.7	9
267	Intraoperative Sentinel Lymph Node Evaluation: Implications of Cytokeratin 19 Expression for the Adoption of OSNA in Oral Squamous Cell Carcinoma. Annals of Surgical Oncology, 2016, 23, 4042-4048.	1.5	9
268	Clinical PET/MR Imaging in Oncology. PET Clinics, 2016, 11, 489-493.	3.0	12
269	PET/MR Imaging in Vascular Disease. PET Clinics, 2016, 11, 479-488.	3.0	6
270	PET/MR Imaging: Clinical Applications. PET Clinics, 2016, 11, xi-xii.	3.0	10

#	Article	IF	Citations
271	PET/MRI: Clinical Applications. PET Clinics, 2016, 11, i.	3.0	O
272	Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. Journal of Nuclear Medicine, 2016, 57, 1851-1857.	5 <b>.</b> 0	29
273	Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180. Journal of Pathology, 2016, 238, 120-133.	4.5	25
274	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	1.9	83
275	C4.4A gene ablation is compatible with normal epidermal development and causes modest overt phenotypes. Scientific Reports, 2016, 6, 25833.	3.3	10
276	Single Particle and PET-based Platform for Identifying Optimal Plasmonic Nano-Heaters for Photothermal Cancer Therapy. Scientific Reports, 2016, 6, 30076.	3.3	55
277	Neuroticism, depression and anxiety in takotsubo cardiomyopathy. BMC Cardiovascular Disorders, 2016, 16, 118.	1.7	16
278	Mouse Positron Emission Tomography Study of the Biodistribution of Gold Nanoparticles with Different Surface Coatings Using Embedded Copper-64. ACS Nano, 2016, 10, 9887-9898.	14.6	48
279	Cross-calibration of the Siemens mMR: easily acquired accurate PET phantom measurements, long-term stability and reproducibility. EJNMMI Physics, 2016, 3, 11.	2.7	11
280	Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 507-513.	2.1	11
281	Quantitative PET Imaging of Tissue Factor Expression Using <sup>18</sup> F-Labeled Active Site–Inhibited Factor VII. Journal of Nuclear Medicine, 2016, 57, 89-95.	5.0	18
282	Impaired cardiac PET image quality due to delayed 82Rubidium dose delivery to the heart. Journal of Nuclear Cardiology, 2016, 23, 1173-1175.	2.1	1
283	Rubidium-82 uptake in metastases from neuroendocrine tumors: No flow response to adenosine. Journal of Nuclear Cardiology, 2016, 23, 840-842.	2.1	6
284	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	5.3	78
285	Feasibility of Real-Time Near-Infrared Fluorescence Tracer Imaging in Sentinel Node Biopsy for Oral Cavity Cancer Patients. Annals of Surgical Oncology, 2016, 23, 565-572.	1.5	63
286	The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts. BMC Medical Imaging, 2016, 16, 5.	2.7	10
287	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. Cardiovascular Diabetology, 2016, 15, 67.	6.8	8
288	Microbiota-Dependent Marker TMAO Is Elevated in Silent Ischemia but Is Not Associated With First-Time Myocardial Infarction in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 130-136.	2.1	41

#	Article	IF	Citations
289	Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. Diabetologia, 2016, 59, 371-378.	6.3	63
290	64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2. Journal of Nuclear Medicine, 2016, 57, 437-443.	5.0	15
291	In vivo evaluation of PEGylated 64Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 941-952.	6.4	36
292	Soluble urokinase plasminogen activator receptor (su <scp>PAR</scp> ) is a novel, independent predictive marker of myocardial infarction in <scp>HIV</scp> â€1â€infected patients: a nested caseâ€control study. HIV Medicine, 2016, 17, 350-357.	2.2	18
293	Comparison of 18F-FET and 18F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma. Nuclear Medicine and Biology, 2016, 43, 198-205.	0.6	10
294	Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Journal of Nuclear Medicine, 2016, 57, 272-278.	5.0	27
295	Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 76.	3.3	30
296	Abstract 460: <sup>64</sup> Cu-DOTATATE for in vivo Positron Emission Tomography Imaging of Somatostatin Receptor 2 Expressing Macrophages in a Göttingen Minipig Model of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	2.4	0
297	Abstract 4771: PET imaging of tissue factor using 64Cu-labeled active site-inhibited factor VII: A potential companion diagnostic for tissue factor targeted cancer therapies. , 2016, , .		0
298	Abstract 5187: PET imaging of trastuzumab emtansine (T-DM1) drug delivery to intracranial patient derived xenograft (PDX) models of breast cancer metastasis. , 2016, , .		0
299	(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 59-72.	1.0	14
300	Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 277-285.	1.0	9
301	Normal Myocardial Flow Reserve in HIV-Infected Patients on Stable Antiretroviral Therapy. Medicine (United States), 2015, 94, e1886.	1.0	15
302	Efficient Regioselective Ring Opening of Activated Aziridineâ€2 arboxylates with [ <sup>18</sup> F]Fluoride. ChemistryOpen, 2015, 4, 65-71.	1.9	8
303	[ <sup>64</sup> Cu]â€labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 227-233.	1.0	16
304	Coronary flow velocity reserve by echocardiography: feasibility, reproducibility and agreement with PET in overweight and obese patients with stable and revascularized coronary artery disease. Cardiovascular Ultrasound, 2015, 14, 22.	1.6	40
305	ANGI-11VEGF-C CONTRIBUTES TO AUTOCRINE VEGFR2 SIGNALING AND AFFECTS CELL VIABILITY AND TUMOR GROWTH IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v43.2-v43.	1.2	0
306	Synthesis and characterization of <sup>18</sup> Fâ€labeled active site inhibited factor VII (ASIS). Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 196-201.	1.0	8

#	Article	IF	Citations
307	Region specific optimization of continuous linear attenuation coefficients based on UTE (RESOLUTE): application to PET/MR brain imaging. Physics in Medicine and Biology, 2015, 60, 8047-8065.	3.0	104
308	Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. Diagnostics, 2015, 5, 96-112.	2.6	1
309	Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics, 2015, 5, 119-176.	2.6	87
310	In Vivo Phenotyping of Tumor Metabolism in a Canine Cancer Patient with Simultaneous 18F-FDG-PET and Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging (hyperPET): Mismatch Demonstrates that FDG may not Always Reflect the Warburg Effect. Diagnostics, 2015, 5, 287-289.	2.6	10
311	Introducing Interesting Images. Diagnostics, 2015, 5, 294-295.	2.6	3
312	Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation (18F-FDG, 64Cu-ATSM and) Tj ETQq0 (Monitoring. Diagnostics, 2015, 5, 372-382.	0 0 rgBT /C 2.6	Overlock 10 T 2
313	Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1. Genes, 2015, 6, 1-21.	2.4	53
314	18F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PIGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma. PLoS ONE, 2015, 10, e0115315.	2.5	8
315	Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients. PLoS ONE, 2015, 10, e0117627.	2.5	26
316	PET/CT Based In Vivo Evaluation of 64Cu Labelled Nanodiscs in Tumor Bearing Mice. PLoS ONE, 2015, 10, e0129310.	2.5	22
317	Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial. PLoS ONE, 2015, 10, e0138124.	2.5	2
318	Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis. PLoS ONE, 2015, 10, e0141379.	2.5	4
319	First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics, 2015, 5, 1303-1316.	10.0	92
320	Imaging Atherosclerosis with Hybrid Positron Emission Tomography/Magnetic Resonance Imaging. BioMed Research International, 2015, 2015, 1-8.	1.9	14
321	Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. ACS Nano, 2015, 9, 6985-6995.	14.6	220
322	<sup>64</sup> Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1696-1703.	2.4	108
323	Nuclear Medicine Imaging in Neuroendocrine Tumors. , 2015, , 131-142.		0
324	<sup>64</sup> Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with <sup>68</sup> Ga-DOTATOC in 60 Patients. Journal of Nuclear Medicine, 2015, 56, 1895-1900.	5.0	67

#	Article	IF	Citations
325	Comparison of the Photothermal Efficiency of Different Types of Plasmonic Nanoparticles in vitro and in vivo. Biophysical Journal, 2015, 108, 171a.	0.5	0
326	Motion correction in simultaneous PET/MR brain imaging using sparsely sampled MR navigators: a clinically feasible tool. EJNMMI Physics, 2015, 2, 14.	2.7	28
327	The impact of weakly bound 89Zr on preclinical studies: Non-specific accumulation in solid tumors and aspergillus infection. Nuclear Medicine and Biology, 2015, 42, 360-368.	0.6	32
328	Reproducibility of <sup> 18 &lt; /sup &gt; F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR. British Journal of Radiology, 2015, 88, 20140655.</sup>	2.2	31
329	HIV infection and arterial inflammation assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET): A prospective cross-sectional study. Journal of Nuclear Cardiology, 2015, 22, 372-380.	2.1	24
330	Injectable Colloidal Gold for Use in Intrafractional 2D Imageâ€Guided Radiation Therapy. Advanced Healthcare Materials, 2015, 4, 856-863.	7.6	29
331	<sup>64</sup> Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with <sup>111</sup> In-DTPA-Octreotide in 112 Patients. Journal of Nuclear Medicine, 2015, 56, 847-854.	<b>5.</b> 0	115
332	Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scandinavian Journal of Gastroenterology, 2015, 50, 740-747.	1.5	50
333	Basal hyperaemia is the primary abnormality of perfusion in Takotsubo cardiomyopathy: a quantitative cardiac perfusion positron emission tomography study. European Heart Journal Cardiovascular Imaging, 2015, 16, 1162-1169.	1.2	16
334	Automated synthesis and PET evaluation of both enantiomers of [18F]FMISO. Nuclear Medicine and Biology, 2015, 42, 413-419.	0.6	7
335	Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. EJNMMI Physics, 2015, 2, 8.	2.7	18
336	Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology, 2015, 17, 595-608.	2.6	56
337	Imaging Macrophage and Hematopoietic Progenitor Proliferation in Atherosclerosis. Circulation Research, 2015, 117, 835-845.	<b>4.</b> 5	72
338	Simultaneous Hyperpolarized <sup>13</sup> C-Pyruvate MRI and <sup>18</sup> F-FDG PET (HyperPET) in 10 Dogs with Cancer. Journal of Nuclear Medicine, 2015, 56, 1786-1792.	5.0	54
339	Low prevalence of peripheral arterial disease in a cross-sectional study of Danish HIV-infected patients. Infectious Diseases, 2015, 47, 776-782.	2.8	15
340	Bringing Radiotracing to Titanium-Based Antineoplastics: Solid Phase Radiosynthesis, PET and ex Vivo Evaluation of Antitumor Agent [ <sup>45</sup> Ti](salan)Ti(dipic). Journal of Medicinal Chemistry, 2015, 58, 7591-7595.	6.4	36
341	Remote Loading of <sup>64</sup> Cu <sup>2+</sup> into Liposomes without the Use of Ion Transport Enhancers. ACS Applied Materials & Samp; Interfaces, 2015, 7, 22796-22806.	8.0	35
342	Treatment of subclinical hyperthyroidism: effect on left ventricular mass and function of the heart using magnetic resonance imaging technique. Endocrine Connections, 2015, 4, 37-42.	1.9	11

#	Article	IF	CITATIONS
343	Selection of suitable reference genes for normalization of genes of interest in canine soft tissue sarcomas using quantitative realâ€time polymerase chain reaction. Veterinary and Comparative Oncology, 2015, 13, 485-493.	1.8	8
344	In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography. Oncotarget, 2015, 6, 37486-37499.	1.8	15
345	Quantitative gene expression underlying 18f-fluorodeoxyglucose uptake in colon cancer Journal of Clinical Oncology, 2015, 33, 653-653.	1.6	0
346	Abstract 4170: The role of VEGF-C for cell viability, tumor growth and bevacizumab resistance in glioblastoma multiforme. , 2015, , .		0
347	Abstract 5174: Imaging of tissue factor expression in an orthotopic pancreatic tumor mouse model using small animal PET/CT and MRI. , 2015, , .		0
348	Abstract 3227: Advanced imaging with PET and MRI in Temozolomide sensitive and resistant subcutaneous and orthotopic patient-derived xenograft (PDX) glioblastoma models., 2015,,.		0
349	Abstract A15: Efficacy of trastuzumab emtansine (T-DM1) in subcutaneous and intracranial patient derived xenograft models of breast cancer metastasis. , $2015$ , , .		0
350	Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 38-45.	1.0	25
351	(18)F-FDG PET imaging in detection of radiation-induced vascular disease in lymphoma survivors. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 408-15.	1.0	3
352	Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 431-56.	1.0	24
353	Quantitative myocardial blood flow with Rubidium-82 PET: a clinical perspective. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 457-68.	1.0	19
354	The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 548-60.	1.0	32
355	BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography. PLoS ONE, 2014, 9, e96736.	2.5	81
356	18F-FDG and 18F-FLT-PET Imaging for Monitoring Everolimus Effect on Tumor-Growth in Neuroendocrine Tumors: Studies in Human Tumor Xenografts in Mice. PLoS ONE, 2014, 9, e91387.	2.5	26
357	Endoscopic versus open radial artery harvest and mammario-radial versus aorto-radial grafting in patients undergoing coronary artery bypass surgery: protocol for the 2 × 2 factorial designed randomised NEO trial. Trials, 2014, 15, 135.	1.6	6
358	Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. Journal of Cancer, 2014, 5, 628-632.	2.5	39
359	Increased prevalence of coronary artery disease risk markers in patients with chronic hepatitis C – a cross-sectional study. Vascular Health and Risk Management, 2014, 10, 55.	2.3	36
360	Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature. Cancer Biology and Therapy, 2014, 15, 862-877.	3.4	9

#	Article	IF	Citations
361	Alternative Polyadenylation of Tumor Suppressor Genes in Small Intestinal Neuroendocrine Tumors. Frontiers in Endocrinology, 2014, 5, 46.	3.5	12
362	Positron emission tomography/computed tomography for optimized colon cancer staging and follow up. Scandinavian Journal of Gastroenterology, 2014, 49, 191-201.	1.5	25
363	Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. Scandinavian Journal of Gastroenterology, 2014, 49, 362-372.	1.5	22
364	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open, 2014, 4, e004227.	1.9	15
365	PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncology, 2014, 10, 2259-2277.	2.4	150
366	Positron emission tomography of the vulnerable atherosclerotic plaque in man $\hat{a}\in$ a contemporary review. Clinical Physiology and Functional Imaging, 2014, 34, 413-425.	1.2	11
367	Injectable Colloidal Gold in a Sucrose Acetate Isobutyrate Gelating Matrix with Potential Use in Radiation Therapy. Advanced Healthcare Materials, 2014, 3, 1680-1687.	7.6	25
368	Review: comparison of <scp>PET</scp> rubidiumâ€82 with conventional <scp>SPECT</scp> myocardial perfusion imaging. Clinical Physiology and Functional Imaging, 2014, 34, 163-170.	1.2	38
369	Only minor additional metabolic health benefits of high as opposed to moderate dose physical exercise in young, moderately overweight men. Obesity, 2014, 22, 1220-1232.	3.0	26
370	PET/CT in therapy evaluation of patients with lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 595-620.	2.4	8
371	Hybrid imaging with PET/CT and PET/MR. Cancer Imaging, 2014, 14, .	2.8	7
372	Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study. Radiation Oncology, 2014, 9, 228.	2.7	18
373	Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. EJNMMI Physics, 2014, 1, 101.	2.7	42
374	Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. Aids, 2014, 28, 1171-1179.	2.2	22
375	Positron Emission Tomography/Computed Tomography and Biomarkers for Early Treatment Response Evaluation in Metastatic Colon Cancer. Oncologist, 2014, 19, 164-172.	3.7	13
376	Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neurolmage, 2014, 84, 206-216.	4.2	170
377	Quantification of myocardial perfusion using cardiac magnetic resonance imaging correlates significantly to rubidium-82 positron emission tomography in patients with severe coronary artery disease: A preliminary study. European Journal of Radiology, 2014, 83, 1120-1128.	2.6	16
378	Non-Invasive Imaging for Subclinical Coronary Atherosclerosis in Patients with Peripheral Artery Disease. Current Atherosclerosis Reports, 2014, 16, 415.	4.8	9

#	Article	IF	Citations
379	The clinical value of cardiac sympathetic imaging in heart failure. Clinical Physiology and Functional Imaging, 2014, 34, 178-182.	1.2	11
380	uPAR Targeted Radionuclide Therapy with <sup>177</sup> Lu-DOTA-AE105 Inhibits Dissemination of Metastatic Prostate Cancer. Molecular Pharmaceutics, 2014, 11, 2796-2806.	4.6	34
381	Positron Emission Tomography Based Analysis of Long-Circulating Cross-Linked Triblock Polymeric Micelles in a U87MG Mouse Xenograft Model and Comparison of DOTA and CB-TE2A as Chelators of Copper-64. Biomacromolecules, 2014, 15, 1625-1633.	5.4	32
382	Sparsely sampled MR navigators as a practical tool for quality control and correction of head motion in simultaneous PET/MR. EJNMMI Physics, 2014, 1, A36.	2.7	3
383	PET/MR imaging of sarcomas: effect of PET quantification by classification of tissue. EJNMMI Physics, 2014, 1, A67.	2.7	2
384	Identification and characterization of human brown adipose tissue (BAT) content and metabolism in adults using [18F]-FDG PET/MR – a pilot study. EJNMMI Physics, 2014, 1, A68.	2.7	5
385	Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications. EJNMMI Physics, 2014, 1, A76.	2.7	3
386	Cardiac 99mTc sestamibi SPECT and 18F FDG PET as viability markers in takotsubo cardiomyopathy. International Journal of Cardiovascular Imaging, 2014, 30, 1407-1416.	1.5	17
387	Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging. Nuclear Medicine and Biology, 2014, 41, 290-295.	0.6	22
388	Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors. Nuclear Medicine and Biology, 2014, 41, 259-267.	0.6	55
389	The Use of Longitudinal 18F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts. PLoS ONE, 2014, 9, e100009.	2.5	19
390	Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study. PLoS ONE, 2014, 9, e109179.	2.5	15
391	Abstract 2070:In vivoimaging of therapy response to novel antibody mixtures targeted at the human epidermal growth factor receptor family using FDG and FLT positron emission tomography. , 2014, , .		0
392	Abstract 4930: Quantitative PET imaging of tissue factor expression using 18F-labeled active site inhibited factor VIIa. , 2014, , .		0
393	Feasibility of simultaneous PET/MR in diet-induced atherosclerotic minipig: a pilot study for translational imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 448-58.	1.0	12
394	Kinetic modeling in PET imaging of hypoxia. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 490-506.	1.0	17
395	PET/MRI in cancer patients: first experiences and vision from Copenhagen. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 37-47.	2.0	32
396	Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested caseâ€"control study. BMC Infectious Diseases, 2013, 13, 230.	2.9	16

#	Article	IF	Citations
397	[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer, 2013, 13, 168.	2.6	22
398	Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 173-181.	2.0	119
399	Copenhagen study of overweight patients with coronary artery disease undergoing low energy diet or interval training: the randomized CUT-IT trial protocol. BMC Cardiovascular Disorders, 2013, 13, 106.	1.7	15
400	Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiation Oncology, 2013, 8, 262.	2.7	16
401	First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts. Nuclear Medicine and Biology, 2013, 40, 618-624.	0.6	44
402	High tumor uptake of 64Cu: Implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nuclear Medicine and Biology, 2013, 40, 345-350.	0.6	76
403	Small animal positron emission tomography imaging and <i>in vivo</i> studies of atherosclerosis. Clinical Physiology and Functional Imaging, 2013, 33, 173-185.	1.2	4
404	Angiographic Features and Cardiovascular Risk Factors in Human Immunodeficiency Virus-Infected Patients With First-Time Acute Coronary Syndrome. American Journal of Cardiology, 2013, 111, 63-67.	1.6	11
405	Exercise training favors increased insulin-stimulated glucose uptake in skeletal muscle in contrast to adipose tissue: a randomized study using FDG PET imaging. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E496-E506.	3.5	52
406	Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor. Diagnostics, 2013, 3, 344-355.	2.6	26
407	Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation. Diagnostics, 2013, 3, 372-384.	2.6	18
408	Urokinaseâ€type plasminogen activator receptor ( <scp>uPAR</scp> ) as a promising new imaging target: potential clinical applications. Clinical Physiology and Functional Imaging, 2013, 33, 329-337.	1.2	41
409	Improved PET Imaging of uPAR Expression Using new 64Cu-labeled Cross-Bridged Peptide Ligands: Comparative in vitro and in vivo Studies. Theranostics, 2013, 3, 618-632.	10.0	50
410	[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts. PLoS ONE, 2013, 8, e53410.	2.5	20
411	Imaging of Treatment Response to the Combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumors in Mice Using FDG and FLT PET. PLoS ONE, 2013, 8, e85126.	2.5	19
412	Imaging of Metastatic Lymph Nodes by X-ray Phase-Contrast Micro-Tomography. PLoS ONE, 2013, 8, e54047.	2.5	13
413	Silent Ischemic Heart Disease and Pericardial Fat Volume in HIV-Infected Patients: A Case-Control Myocardial Perfusion Scintigraphy Study. PLoS ONE, 2013, 8, e72066.	2.5	30
414	Plasma natriuretic peptides during supraventricular tachycardia: A study in patients with atrioventricular nodal reentry tachycardia. World Journal of Cardiovascular Diseases, 2013, 03, 471-475.	0.2	0

#	Article	IF	CITATIONS
415	Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 361-71.	1.0	53
416	(18)F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1α. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 384-92.	1.0	18
417	Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 4, 17-28.	1.0	42
418	111Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats. International Journal of Molecular Imaging, 2012, 2012, 1-7.	1.3	2
419	Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with <sup>64</sup> Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion. Journal of Nuclear Medicine, 2012, 53, 138-145.	5.0	73
420	Uphill running improves rat Achilles tendon tissue mechanical properties and alters gene expression without inducing pathological changes. Journal of Applied Physiology, 2012, 113, 827-836.	2.5	64
421	Clinical PET of Neuroendocrine Tumors Using <sup>64</sup> Cu-DOTATATE: First-in-Humans Study. Journal of Nuclear Medicine, 2012, 53, 1207-1215.	5.0	147
422	Cardiovascular disease in patients with HIV. Future Virology, 2012, 7, 413-423.	1.8	6
423	Preoperative PET/CT in early-stage breast cancer. Annals of Oncology, 2012, 23, 2277-2282.	1.2	66
424	<sup>64</sup> Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: Correlation between Tumor Uptake and Integrin Expression in Human Neuroendocrine Tumor Xenografts. International Journal of Molecular Imaging, 2012, 2012, 1-11.	1.3	21
425	Importance of Attenuation Correction (AC) for Small Animal PET Imaging. Diagnostics, 2012, 2, 42-51.	2.6	20
426	Hepatitis <scp>C</scp> virus infection and risk of coronary artery disease: a systematic review of the literature. Clinical Physiology and Functional Imaging, 2012, 32, 421-430.	1.2	39
427	Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiotherapy and Oncology, 2012, 102, 424-428.	0.6	36
428	First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience. Acta Oncol $\tilde{A}^3$ gica, 2012, 51, 97-100.	1.8	15
429	PET imaging of liposomes labeled with an [ <sup>18</sup> F]-fluorocholesteryl ether probe prepared by automated radiosynthesis. Journal of Liposome Research, 2012, 22, 295-305.	3.3	13
430	68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nuclear Medicine and Biology, 2012, 39, 560-569.	0.6	51
431	Changes in lung function of <scp>HIV</scp> â€infected patients: a 4·5â€year followâ€up study. Clinical Physiology and Functional Imaging, 2012, 32, 288-295.	1.2	51
432	New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nuclear Medicine and Biology, 2012, 39, 962-969.	0.6	36

#	Article	IF	CITATIONS
433	Takotsubo-cardiomyopathy: A case of extremely fast recovery described by multimodality cardiac imaging. Journal of Nuclear Cardiology, 2012, 19, 1240-1242.	2.1	10
434	64Cu-ATSM and 18FDG PET uptake and 64Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiation Oncology, 2012, 7, 89.	2.7	36
435	The Combination of In vivo 124I-PET and CT Small Animal Imaging for Evaluation of Thyroid Physiology and Dosimetry. Diagnostics, 2012, 2, 10-22.	2.6	6
436	Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas. Scientific World Journal, The, 2012, 2012, 1-4.	2.1	57
437	Microvessel Density But Not Neoangiogenesis Is Associated with 18F-FDG Uptake in Human Atherosclerotic Carotid Plaques. Molecular Imaging and Biology, 2012, 14, 384-392.	2.6	20
438	Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. Journal of Controlled Release, 2012, 160, 254-263.	9.9	65
439	NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. Cardiovascular Diabetology, 2012, 11, 19.	6.8	12
440	Preserved myocardial blood flow in the apical region involved in takotsubo cardiomyopathy by quantitative cardiac PET assessment. Journal of Nuclear Cardiology, 2012, 19, 169-171.	2.1	8
441	[18F]FLT PET for Non-Invasive Assessment of Tumor Sensitivity to Chemotherapy: Studies with Experimental Chemotherapy TP202377 in Human Cancer Xenografts in Mice. PLoS ONE, 2012, 7, e50618.	2.5	9
442	18F-FDG PET Imaging of Murine Atherosclerosis: Association with Gene Expression of Key Molecular Markers. PLoS ONE, 2012, 7, e50908.	2.5	40
443	Atrial Natriuretic Peptide and Acute Changes in Central Blood Volume by Hyperthermia in Healthy Humans. Open Neuroendocrinology Journal (Online), 2012, 5, 1-4.	0.4	7
444	Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scandinavian Cardiovascular Journal, 2011, 45, 161-168.	1.2	69
445	NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. Cardiovascular Diabetology, 2011, 10, 71.	6.8	26
446	A randomized study of the effects of exercise training on patients with atrial fibrillation. American Heart Journal, 2011, 162, 1080-1087.	2.7	78
447	Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology, 2011, 38, 509-515.	0.6	15
448	Use of Cis-[18F]Fluoro-Proline for Assessment of Exercise-Related Collagen Synthesis in Musculoskeletal Connective Tissue. PLoS ONE, 2011, 6, e16678.	2.5	13
449	Flow-Mediated Vasodilatation and Intima-Media Thickness in Patients with Coexisting Heart Failure and Diabetes Receiving Medical Therapy. Diagnostics, 2011, 1, 38-52.	2.6	2
450	Differential glucose uptake in quadriceps and other leg muscles during one-legged dynamic submaximal knee-extension exercise. Frontiers in Physiology, 2011, 2, 75.	2.8	13

#	Article	IF	Citations
451	Welcome to Diagnostics: a New Open Access Journal for the Fast-Growing Field of Medical Diagnostics. Diagnostics, 2011, 1, 36-37.	2.6	0
452	Decreased Heart Rate Variability in HIV Positive Patients Receiving Antiretroviral Therapy: Importance of Blood Glucose and Cholesterol. PLoS ONE, 2011, 6, e20196.	2.5	26
453	Molecular Imaging with Small Animal PET/CT. Current Medical Imaging, 2011, 7, 234-247.	0.8	11
454	Carotid plaque imaging with FDG-PET and ultrasound. Imaging in Medicine, 2011, 3, 17-30.	0.0	3
455	Limited value of novel pulmonary embolism biomarkers in patients with coronary atherosclerosis. Clinical Physiology and Functional Imaging, 2011, 31, 452-457.	1.2	2
456	Cardiac function in growth hormone deficient patients before and after $1\text{\^{A}}$ year with replacement therapy: a magnetic resonance imaging study. Pituitary, 2011, 14, 1-10.	2.9	25
457	Recombinant coagulation factor VIIa labelled with the <i>fac&lt; i&gt;â€<sup>99 m</sup>Tc(CO)<sub>3</sub>â€core: synthesis and <i>in vitro</i> evaluation of a putative new radiopharmaceutical for imaging in acute bleeding lesion. Journal of Labelled Compounds and Radiopharmaceuticals. 2011. 54. 214-219.</i>	1.0	6
458	64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials, 2011, 32, 2334-2341.	11.4	123
459	FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO Journal, 2011, 30, 4554-4570.	7.8	103
460	Peptide Receptor Radionuclide Therapy with <sup>90</sup> Y-DOTATOC and <sup>177</sup> Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland. Neuroendocrinology, 2011, 93, 189-196.	2.5	122
461	Increased Plasma Aldosterone during Atrial Fibrillation Declines following Cardioversion. Cardiology, 2011, 118, 239-244.	1.4	7
462	Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. Cardiovascular Diabetology, 2011, 10, 70.	6.8	14
463	Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes. Current Drug Targets, 2011, 12, 1711-1728.	2.1	59
464	Interferon- $\hat{l}^3$ inhibits ghrelin expression and secretion via a somatostatin-mediated mechanism. World Journal of Gastroenterology, 2011, 17, 3117-25.	3.3	6
465	Ventilation/Perfusion Imaging with SPECT-CT., 2011, , 195-202.		0
466	Abstract 5320: Changes in [18]F-FLT and [18]F-FDG positron emission tomography following treatment with belinostat alone and in combination with paclitaxel/carboplatin in human ovary cancer xenografts in mice., 2011,,.		0
467	Abstract 5315: PET imaging with the proliferation tracer $18F$ -FLT as early, non-invasive predictor of everolimus effect on tumor growth: Studies in human neuroendocrine tumor xenografts in mice. , $2011, \ldots$		0
468	Abstract 5308: PET imaging of hypoxia with [64]Cu-ATSM in human ovarian cancer: Comparison of xenografts in mice and rats., $2011$ ,,.		2

#	Article	IF	Citations
469	Abstract 5280: PET imaging of proteolysis: Evaluation of 68Ga-DOTA and 68Ga-NODAGA chelates of an uPAR-specific peptide in a human glioblastoma xenograft model. , 2011, , .		O
470	Comparison of V/Q SPECT and planar V/Q lung scintigraphy in diagnosing acute pulmonary embolism. Nuclear Medicine Communications, 2010, 31, 82-86.	1.1	94
471	When to image carotid plaque inflammation with FDG PET/CT. Nuclear Medicine Communications, 2010, 31, 773-779.	1.1	21
472	Serial in vivo imaging of the porcine heart after percutaneous, intramyocardially injected 111In-labeled human mesenchymal stromal cells. International Journal of Cardiovascular Imaging, 2010, 26, 273-284.	1.5	19
473	Increased Cellular Proliferation in Rat Skeletal Muscle and Tendon in Response to Exercise: Use of FLT and PET/CT. Molecular Imaging and Biology, 2010, 12, 626-634.	2.6	9
474	Cardiac effects of 3Âmonths treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary, 2010, 13, 329-336.	2.9	17
475	Fluorineâ€18 labelling of a series of potential EGFRvIII targeting peptides with a parallel labelling approach using [ <sup>18</sup> F]FPyME. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 774-778.	1.0	7
476	Estimating GFR in children with <sup>99m</sup> Tcâ€DTPA renography: a comparison with singleâ€sample <sup>51</sup> Crâ€EDTA clearance. Clinical Physiology and Functional Imaging, 2010, 30, 169-174.	1.2	17
477	ANP, BNP and Dâ€dimer predict right ventricular dysfunction in patients with acute pulmonary embolism. Clinical Physiology and Functional Imaging, 2010, 30, 466-472.	1,2	20
478	Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice. PLoS ONE, 2010, 5, e12965.	2.5	36
479	Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, $\langle sup \rangle 123 \langle sup \rangle I-MIBG$ Scintigraphy, and $\langle sup \rangle 18 \langle sup \rangle I-F-FDG$ PET. Journal of Nuclear Medicine, 2010, 51, 704-712.	5.0	269
480	18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors. Clinical Cancer Research, 2010, 16, 978-985.	7.0	413
481	Reply: Routine Use of a V/Q SPECT/Low-Dose CT Hybrid System to Diagnose Pulmonary Embolism Seems Premature. Journal of Nuclear Medicine, 2010, 51, 1330-1330.	5.0	0
482	Radiation exposure for medical staff performing quantitative coronary perfusion PET with 13N-ammonia. Radiation Protection Dosimetry, 2010, 138, 107-110.	0.8	5
483	PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel 64Cu-DOTA-Knottin Peptide. Cancer Research, 2010, 70, 9022-9030.	0.9	43
484	Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. American Journal of Physiology - Renal Physiology, 2010, 299, G784-G790.	3.4	8
485	18FDG PET and Ultrasound Echolucency in Carotid Artery Plaques. JACC: Cardiovascular Imaging, 2010, 3, 289-295.	5.3	60
486	Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. Journal of Neuroinflammation, 2010, 7, 13.	7.2	32

#	Article	IF	CITATIONS
487	Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nuclear Medicine Communications, 2010, 31, 423-429.	1.1	99
488	Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nuclear Medicine Communications, 2010, 31, 874-880.	1.1	18
489	Gene Expression of ANP, BNP and ET-1 in the Heart of Rats during Pulmonary Embolism. PLoS ONE, 2010, 5, e11111.	2.5	9
490	Abstract 5237: Non-invasive detection of urokinase-type plasminogen activator receptor (uPAR) expression in four human cancer xenograft mouse models using microPET/CT., 2010,,.		0
491	Abstract 5220: Early prediction of tumor response to APO866 treatment with $3\hat{a} \in \mathbb{Z}$ -deoxy- $3\hat{a} \in \mathbb{Z}$ -[18F]fluorothymidine positron emission tomography in human ovary cancer xenografts in mice. , 2010, , .		0
492	Regional Gene Expression of LOX-1, VCAM-1, and ICAM-1 in Aorta of HIV-1 Transgenic Rats. PLoS ONE, 2009, 4, e8170.	2.5	19
493	Radiation exposure to surgical staff during hyperthermic isolated limb perfusion with99mTechnetium labeled red blood cells. International Journal of Hyperthermia, 2009, 25, 86-89.	2.5	3
494	Detection of Pulmonary Embolism with Combined Ventilation–Perfusion SPECT and Low-Dose CT: Head-to-Head Comparison with Multidetector CT Angiography. Journal of Nuclear Medicine, 2009, 50, 1987-1992.	5.0	202
495	Noninvasive <sup>64</sup> Cu-ATSM and PET/CT Assessment of Hypoxia in Rat Skeletal Muscles and Tendons During Muscle Contractions. Journal of Nuclear Medicine, 2009, 50, 950-958.	5.0	10
496	Molecular Pathology in Vulnerable Carotid Plaques: Correlation with [18]-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET). European Journal of Vascular and Endovascular Surgery, 2009, 37, 714-721.	1.5	128
497	Identification of novel peptide ligands for the cancerâ€specific receptor mutation EFGRvIII using a mixtureâ€based synthetic combinatorial library. Biopolymers, 2009, 91, 201-206.	2.4	24
498	18F-Fluorodeoxyglucose and PET/CT for noninvasive study of exercise-induced glucose uptake in rat skeletal muscle and tendon. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 859-868.	6.4	8
499	Reduction in circulating markers of endothelial dysfunction in HIVâ€infected patients during antiretroviral therapy. HIV Medicine, 2009, 10, 79-87.	2.2	53
500	Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIVâ€1â€infected individuals receiving combination antiretroviral therapy. HIV Medicine, 2009, 10, 627-633.	2.2	31
501	Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. Diabetes Research and Clinical Practice, 2009, 84, 34-38.	2.8	8
502	Right and left sided cardiac function in HIV patients on anti-retroviral therapy: a cine magnetic resonance imaging study. Journal of Cardiovascular Magnetic Resonance, $2009,11,.$	3.3	1
503	Comparison of [18F]FBA and [18F]FPyMe as peptide radio-labeling agents of PEPHC1 for PET imaging of EGFRvIII. Advances in Experimental Medicine and Biology, 2009, 611, 405-406.	1.6	2
504	Radiation exposure to surgical staff during F-18-FDG-guided cancer surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 624-629.	6.4	20

#	Article	IF	CITATIONS
505	EANM/ESC guidelines for radionuclide imaging of cardiac function. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 851-885.	6.4	184
506	Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2049-2058.	6.4	24
507	Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Medical Imaging, 2008, 8, 16.	2.7	315
508	Effect of eight weeks of endurance exercise training on right and left ventricular volume and mass in untrained obese subjects: a longitudinal MRI study. Scandinavian Journal of Medicine and Science in Sports, 2008, 18, 354-359.	2.9	24
509	Identification of Amino Acid Residues in PEPHC1 Important for Binding to the Tumorâ€Specific Receptor EGFRvIII. Chemical Biology and Drug Design, 2008, 72, 273-278.	3.2	3
510	Effects of passive heating on central blood volume and ventricular dimensions in humans. Journal of Physiology, 2008, 586, 293-301.	2.9	147
511	Right and left cardiac function in HIV-infected patients investigated using radionuclide ventriculography and brain natriuretic peptide: a 5-year follow-up study. HIV Medicine, 2008, 9, 180-186.	2.2	22
512	BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity. International Journal of Cardiology, 2008, 124, 193-197.	1.7	24
513	ANP and BNP in atrial fibrillation before and after cardioversion – and their relationship to cardiac volume and function. International Journal of Cardiology, 2008, 127, 396-399.	1.7	27
514	Gene expression of LOX-1, VCAM-1, and ICAM-1 in pre-atherosclerotic mice. Biochemical and Biophysical Research Communications, 2008, 377, 689-693.	2.1	21
515	Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2008, 87, 223-232.	2.5	43
516	Exerciseâ€induced hypoxia in rat skeletal muscle and tendon. FASEB Journal, 2008, 22, 753.27.	0.5	0
517	Independent effects of both right and left ventricular function on plasma brain natriuretic peptide. European Journal of Heart Failure, 2007, 9, 892-896.	7.1	19
518	Unexplained weekâ€toâ€week variation in BNP and NTâ€proBNP is low in chronic heart failure patients during steady state. European Journal of Heart Failure, 2007, 9, 68-74.	7.1	74
519	Effects of Body Mass Index and Age on N-Terminal Pro–Brain Natriuretic Peptide Are Associated with Glomerular Filtration Rate in Chronic Heart Failure Patients. Clinical Chemistry, 2007, 53, 1928-1935.	3.2	25
520	Histamine and the Regulation of Body Weight. Neuroendocrinology, 2007, 86, 210-214.	2.5	60
521	Automated interpretation of PET/CT images in patients with lung cancer. Nuclear Medicine Communications, 2007, 28, 79-84.	1.1	12
522	The relationship between N-terminal pro–brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. American Heart Journal, 2007, 154, 123-129.	2.7	21

#	Article	IF	Citations
523	Advanced Quantitative Echocardiography in Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of the American Society of Echocardiography, 2007, 20, 27-35.	2.8	56
524	Anaemia and NT-proBNP Are Associated and Carry Independent Prognostic Information in Chronic Heart Failure Patients. Journal of Cardiac Failure, 2007, 13, S103-S104.	1.7	0
525	Added value of combined simultaneous lung ventilation?perfusion single-photon emission computed tomography/multi-slice-computed tomography angiography in two patients suspected of having acute pulmonary embolism. Clinical Respiratory Journal, 2007, 1, 52-55.	1.6	9
526	Carotid intima?media thickness in HIV patients treated with antiretroviral therapy. Clinical Physiology and Functional Imaging, 2007, 27, 173-179.	1.2	22
527	Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clinical Physiology and Functional Imaging, 2007, 27, 363-367.	1.2	40
528	Prognostic Usefulness of Anemia and N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Systolic Heart Failure. American Journal of Cardiology, 2007, 100, 1571-1576.	1.6	16
529	Long-Term Clinical Variation of N-Terminal-Pro-Brain-Natriuretic-Peptide in Stable Chronic Heart Failure Patients. Journal of Cardiac Failure, 2006, 12, S34.	1.7	0
530	Nitric oxide and prostaglandins influence local skeletal muscle blood flow during exercise in humans: coupling between local substrate uptake and blood flow. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R803-R809.	1.8	23
531	Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake. Clinical Physiology and Functional Imaging, 2006, 26, 167-170.	1.2	17
532	The plasma atrial natriuretic peptide response to arm and leg exercise in humans: effect of posture. Experimental Physiology, 2006, 91, 765-771.	2.0	19
533	Labelling of human mesenchymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1171-1177.	6.4	97
534	Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. European Heart Journal, 2006, 28, 177-182.	2.2	61
535	Increased Susceptibility to Diet-Induced Obesity in Histamine-Deficient Mice. Neuroendocrinology, 2006, 83, 289-294.	2.5	44
536	Self-Reported Fatigue Common among Optimally Treated HIV Patients: No Correlation with Cerebral FDG-PET Scanning Abnormalities. NeuroImmunoModulation, 2006, 13, 69-75.	1.8	15
537	Right Ventricular Volume and Mass Determined by Cine Magnetic Resonance Imaging in HIV Patients with Possible Right Ventricular Dysfunction. Angiology, 2006, 57, 341-346.	1.8	5
538	Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiologica, 2006, 47, 248-256.	1.1	50
539	Evaluation of left ventricular mass measured by 3D echocardiography using magnetic resonance imaging as gold standard. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 647-658.	1.2	15
540	Evaluation of right ventricular volume and function by 2D and 3D echocardiography compared to MRI. European Journal of Echocardiography, 2006, 7, 430-438.	2.3	249

#	Article	IF	Citations
541	Molecular imaging of cancer using PET and SPECT. Advances in Experimental Medicine and Biology, 2006, 587, 277-84.	1.6	12
542	Early clinical experience and impact of 18F-FDG PET. Nuclear Medicine Communications, 2005, 26, 989-994.	1.1	12
543	Bone infection in patients suspected of complicating osteomyelitis: the diagnostic value of dual isotope bone-granulocyte scintigraphy. Clinical Physiology and Functional Imaging, 2005, 25, 20-26.	1.2	6
544	Rightâ€sided cardiac function in healthy volunteers measured by firstâ€pass radionuclide ventriculography and gated bloodâ€pool SPECT: comparison with cine MRI. Clinical Physiology and Functional Imaging, 2005, 25, 344-349.	1.2	37
545	Positron Emission Tomographic Evaluation of Regulation of Myocardial Perfusion in Physiological (Elite Athletes) and Pathological (Systemic Hypertension) Left Ventricular Hypertrophy. American Journal of Cardiology, 2005, 96, 1692-1698.	1.6	35
546	EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 855-897.	6.4	467
547	16S rDNA sequencing revealed Citrobacter freundii as the cause of liver abcess after banding of rectal haemorrhoids. Journal of Infection, 2005, 50, 163-164.	3.3	6
548	The effect of dynamic knee-extension exercise on patellar tendon and quadriceps femoris muscle glucose uptake in humans studied by positron emission tomography. Journal of Applied Physiology, 2005, 99, 1189-1192.	2.5	37
549	Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. European Journal of Heart Failure, 2005, 7, 87-93.	7.1	115
550	Histaminergic Neurons Are Involved in the Orexigenic Effect of Orexin-A. Neuroendocrinology, 2005, 82, 70-77.	2.5	22
551	Impact of medical treatment on lung diffusion capacity in elderly patients with heart failure. International Journal of Cardiology, 2005, 98, 453-457.	1.7	4
552	Neurohormones as markers of right- and left-sided cardiac dimensions and function in patients with untreated chronic heart failure. International Journal of Cardiology, 2005, 99, 301-306.	1.7	11
553	Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects. European Journal of Heart Failure, 2004, 6, 29-39.	7.1	35
554	Fever of unknown origin: prospective comparison of diagnostic value of 18 F-FDG PET and 111 In-granulocyte scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 622-626.	6.4	130
555	Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. American Heart Journal, 2004, 147, 482-488.	2.7	23
556	Myocardial perfusion imaging in Denmark: activity from 1997 to 2001 and current practice. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 137-140.	6.4	4
557	Serotonin Receptors Involved in Vasopressin and Oxytocin Secretion. Journal of Neuroendocrinology, 2003, 15, 242-249.	2.6	162
558	Serotonin Stimulates Hypothalamic mRNA Expression and Local Release of Neurohypophysial Peptides. Journal of Neuroendocrinology, 2003, 15, 564-571.	2.6	73

#	Article	IF	Citations
559	Histamine and Prostaglandin Interaction in Regulation of Oxytocin and Vasopressin Secretion. Journal of Neuroendocrinology, 2003, 15, 940-945.	2.6	15
560	Catecholaminergic Activation in Acute Myocardial Infarction: Time Course and Relation to Left Ventricular Performance. Cardiology, 2003, 100, 23-28.	1.4	24
561	The role of hypothalamic histamine in leptin-induced suppression of short-term food intake in fasted rats. Regulatory Peptides, 2003, 111, 83-90.	1.9	33
562	Title is missing!. Clinical Nuclear Medicine, 2003, 28, 506-508.	1.3	0
563	Combined Indium-111 Octreotide Scintigraphy and Low-Dose Computed Tomography in Localization of Neuroendocrine Tumors. Clinical Nuclear Medicine, 2003, 28, 506-508.	1.3	2
564	Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes. Journal of Nuclear Medicine, 2003, 44, 19-23.	5.0	32
565	Serotonergic involvement in stress-induced vasopressin and oxytocin secretion. European Journal of Endocrinology, 2002, 147, 815-824.	3.7	55
566	I-123 MIBG Imaging and Intraoperative Localization of Metastatic Pheochromocytoma. Clinical Nuclear Medicine, 2002, 27, 183-185.	1.3	17
567	Primary Diagnosis of Multiple Pheochromocytomas in the Brother of a MEN-2 Patient by Simultaneous MIBG Scintigraphy and Low-Dose Computed Tomography. Clinical Nuclear Medicine, 2002, 27, 868-870.	1.3	7
568	Utility of Planar Bone Scintigraphy To Distinguish Benign Osteochondromas from Malignant Chondrosarcomas. Clinical Nuclear Medicine, 2002, 27, 622-624.	1.3	25
569	Neurohumoral prediction of left-ventricular morphologic response to β-blockade with metoprolol in chronic left-ventricular systolic heart failure. European Journal of Heart Failure, 2002, 4, 635-646.	7.1	14
570	Effect of Interleukin $1\hat{l}^2$ on the HPA Axis in H<sub>1</sub>-Receptor Knockout Mice. NeuroImmunoModulation, 2002, 10, 344-350.	1.8	4
571	Serotonergic Stimulation of Corticotropin-Releasing Hormone and Pro-Opiomelanocortin Gene Expression. Journal of Neuroendocrinology, 2002, 14, 788-795.	2.6	67
572	Attenuation and scatter correction in myocardial SPET: improved diagnostic accuracy in patients with suspected coronary artery disease. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1438-1442.	6.4	23
573	Diagnostic value of (111)In-granulocyte scintigraphy in patients with fever of unknown origin. Journal of Nuclear Medicine, 2002, 43, 140-4.	5.0	30
574	Editorial. Nuclear Medicine Communications, 2001, 22, 851-855.	1.1	4
575	Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrology, 2001, 2, 1.	1.8	24
576	Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clinical Physiology, 2001, 21, 661-672.	0.7	109

#	Article	IF	CITATIONS
577	Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. European Journal of Heart Failure, 2001, 3, 699-708.	7.1	72
578	Myocardial Hibernation – Land of Ignorance. Scandinavian Cardiovascular Journal, 2001, 35, 228-229.	1.2	1
579	Differential Effect of Serotonin 5-HT <sub>1A</sub> Receptor Antagonists on the Secretion of Corticotropin and Prolactin. Neuroendocrinology, 2001, 73, 322-333.	2.5	21
580	Stress-Induced Release of Anterior Pituitary Hormones: Effect of H <sub>3</sub> Receptor-Mediated Inhibition of Histaminergic Activity or Posterior Hypothalamic Lesion. Neuroendocrinology, 1999, 69, 44-53.	2.5	20
581	Effect of Selective Blockade of Catecholaminergic Alpha and Beta Receptors on Histamine-Induced Release of Corticotropin and Prolactin. Neuroendocrinology, 1999, 69, 309-315.	2.5	9
582	Histaminergic and Catecholaminergic Interactions in the Central Regulation of Vasopressin and Oxytocin Secretion*. Endocrinology, 1999, 140, 3713-3719.	2.8	51
583	Adrenocorticotropic Hormone Secretion in Rats Induced by Stimulation with Serotonergic Compounds. Journal of Neuroendocrinology, 1999, 11, 283-290.	2.6	34
584	Histaminergic and Catecholaminergic Interactions in the Central Regulation of Vasopressin and Oxytocin Secretion. Endocrinology, 1999, 140, 3713-3719.	2.8	14
585	Serotonergic involvement in stress-induced ACTH release. Brain Research, 1998, 811, 10-20.	2.2	62
586	Selective Inhibition of Magnocellular Vasopressin Neurons by Hypoosmolality: Effect on Histamine- and Stress-Induced Secretion of Adrenocorticotropin and Prolactin. Neuroendocrinology, 1998, 67, 330-335.	2.5	4
587	Neuronal histamine and expression of corticotropin-releasing hormone, vasopressin and oxytocin in the hypothalamus: relative importance of H1 and H2 receptors. European Journal of Endocrinology, 1998, 139, 238-243.	3.7	46
588	Dehydration-Induced Renin Secretion: Involvement of Histaminergic Neurons. Neuroendocrinology, 1998, 67, 325-329.	2.5	8
589	Histamine and Prostaglandin Interaction in the Central Regulation of ACTH Secretion. Neuroendocrinology, 1997, 66, 68-74.	2.5	18
590	Interactions of Histaminergic and Serotonergic Neurons in the Hypothalamic Regulation of Prolactin and ACTH Secretion. Neuroendocrinology, 1996, 64, 329-336.	2.5	17
591	Involvement of Histamine in Suckling-Induced Release of Oxytocin, Prolactin and Adrenocorticotropin in Lactating Rats. Neuroendocrinology, 1996, 63, 550-558.	2.5	24
592	Neurohypophysial peptides. Histaminergic regulation and function in adenohypophysial secretion. Danish Medical Bulletin, 1996, 43, 391-406.	0.1	0
593	Stress-Induced Secretion of Pro-Opiomelanocortin-Derived Peptides in Rats: Relative Importance of the Anterior and Intermediate Pituitary Lobes. Neuroendocrinology, 1995, 61, 167-172.	2.5	30
594	Effect of Histamine on Gene Expression and Release of Proopiomelanocortin-Derived Peptides from the Anterior and Intermediate Pituitary Lobes in Conscious Male Rats. Neuroendocrinology, 1995, 62, 319-325.	2.5	9

#	Article	IF	Citations
595	Involvement of Oxytocin in Histamine- and Stress-Induced ACTH and Prolactin Secretion. Neuroendocrinology, 1995, 61, 704-713.	2.5	34
596	Dehydration stimulates hypothalamic gene expression of histamine synthesis enzyme: importance for neuroendocrine regulation of vasopressin and oxytocin secretion Endocrinology, 1995, 136, 2189-2197.	2.8	35
597	Histamine stimulates c-fos expression in hypothalamic vasopressin-, oxytocin-, and corticotropin-releasing hormone-containing neurons Endocrinology, 1994, 134, 482-491.	2.8	71
598	Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons Endocrinology, 1994, 135, 675-681.	2.8	70
599	Histaminergic activation of the hypothalamic-pituitary-adrenal axis Endocrinology, 1994, 135, 1171-1177.	2.8	56
600	Histamine- and stress-induced prolactin secretion: importance of vasopressin V1- and V2-receptors. European Journal of Endocrinology, 1994, 131, 391-397.	3.7	8
601	Role of Hypothalamic Histaminergic Neurons in Mediation of ACTH and Beta-Endorphin Responses to LPS Endotoxin in vivo. Neuroendocrinology, 1994, 60, 243-251.	2.5	24
602	Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons. Endocrinology, 1994, 135, 675-681.	2.8	17
603	Histaminergic activation of the hypothalamic-pituitary-adrenal axis. Endocrinology, 1994, 135, 1171-1177.	2.8	20
604	Copper release from copper intrauterine devices removed after up to 8 years of use. Contraception, 1993, 47, 349-358.	1.5	25
605	Insulin/hypoglycemia-induced adrenocorticotropin and beta-endorphin release: involvement of hypothalamic histaminergic neurons Endocrinology, 1993, 132, 2213-2220.	2.8	24
606	Involvement of Vasopressin in Histamine- and Stress-Induced Prolactin Release: Permissive, Mediating or Potentiating Role?. Neuroendocrinology, 1993, 57, 314-321.	2.5	18
607	Impaired Histamine- and Stress-Induced Secretion of ACTH and $\hat{I}^2$ -Endorphin in Vasopressin- Deficient Brattleboro Rats. Neuroendocrinology, 1993, 57, 1035-1041.	2.5	30
608	Involvement of Vasopressin V <sub>1</sub> and V <sub>2</sub> -Receptors in Histamine and Stress-Induced Secretion of ACTH and β-Endorphin. Neuroendocrinology, 1993, 57, 503-509.	2.5	13
609	Permissive, Mediating and Potentiating Effects of Vasopressin in the ACTH and $\hat{I}^2$ -Endorphin Response to Histamine and Restraint Stress. Neuroendocrinology, 1993, 58, 588-596.	2.5	18
610	Responses of Anterior Pituitary Hormones and Hypothalamic Histamine to Blockade of Histamine Synthesis and to Selective Activation or Inactivation of Presynaptic Histamine H <sub>3</sub> Receptors in Stressed Rats. Neuroendocrinology, 1993, 57, 532-540.	2.5	33
611	Histamine- and Stress-Induced Secretion of ACTH and $\hat{I}^2$ -Endorphin: Involvement of Corticotropin-Releasing Hormone and Vasopressin. Neuroendocrinology, 1992, 56, 419-428.	2.5	71
612	Histamine H <sub>1</sub> and H <sub>2</sub> Receptor Activation Stimulates ACTH and β-Endorphin Secretion by Increasing Corticotropin-Releasing Hormone in the Hypophyseal Portal Blood. Neuroendocrinology, 1992, 56, 851-855.	2.5	27

#	Article	IF	CITATIONS
613	Metabolic changes during the normal menstrual cycle: A longitudinal study. American Journal of Obstetrics and Gynecology, 1990, 163, 414-416.	1.3	25
614	Metabolic changes during treatment with two different progestogens. American Journal of Obstetrics and Gynecology, 1990, 163, 374-377.	1.3	33
615	Clinical and hormonal effects of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene. Contraception, 1990, 41, 259-269.	1.5	21
616	Lipid metabolism and coagulation of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene. Contraception, 1989, 40, 665-673.	1.5	37
617	Treatment of subclinical hyperthyroidism: effect on left ventricular mass and function of the heart using MRI technique. Endocrine Abstracts, 0, , .	0.0	0
618	Theranostics for the invasive cancer phenotype: uPAR targeted theranostics. Endocrine Abstracts, 0, , .	0.0	0
619	Myocardial perfusion reserve in patients with chronic hepatitis C before and after Direct Acting Antiviral treatment – a pilot study. Clinical Physiology and Functional Imaging, 0, , .	1.2	1